RxDoctor Payments DataLook up a doctor →

Sheldon Berger, DO

Gastroenterology · Tulsa, OKNPI 1114982089

Payments from drug & device makers

$13,915in general payments, 2019–2025

Across 766 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Gilead$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$1K
  • Pfizer$679
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$13,72099%
  • Education$751%
  • Gifts$1201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,915 in reported general payments places this provider in the 75th percentile of 133 gastroenterology providers in Oklahoma.

See all gastroenterology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$187,647
Medicare patients
426
Services billed
8,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase18$33,358
Mesalamine31$22,385
ClenpiqSod Picosulf/Mag Ox/Citric Ac57$9,988
Pantoprazole Sodium379$6,995
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates54$3,114
Budesonide DrBudesonide21$2,528
Esomeprazole Magnesium12$880
Rabeprazole Sodium26$851
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl48$643
Sucralfate29$564
Ondansetron OdtOndansetron11$529
Omeprazole41$512
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl30$482
Dicyclomine Hcl23$377
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl21$318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$3,880$33,35818 claims
Ferring Pharmaceuticals Inc.Clenpiq$410$9,98857 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 133 gastroenterology providers in Oklahoma.

Other gastroenterology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →